USD10
TGTX Shares
About TG TherapeuticsTG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
USD10
TGTX Shares
About TG TherapeuticsTG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Stats
TRADING WINDOW
Closed
OPENS AT
Aug 11 at 1:30 PM GMT+0
MARKET CAP
$7.71B
OPEN PRICE
Not enough data
LOW (1Y)
$25.28
HIGH (1Y)
$59.30
LOW (24H)
$48.50
HIGH (24H)
$50.39
VOLUME (24H)
$1.00
100%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $49.70 | |
1 Week | $46.30 | |
1 Month | $55.88 | |
1 Year | $27.12 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.